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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.08.003BACKGROUND AND OBJECTIVES: Pediatric patients undergoing hematopoietic stem cell transplant (HSCT)
are at a uniquely high risk of cytomegalovirus (CMV) and Epstein–Barr virus (EBV) infections. The pre-emptive
treatment model whereby asymptomatic post-transplant patients are routinely screened with treatment initiated
if found viremic has recently been shown to be superior in terms of patient mortality when compared to defer-
ring laboratory assessment and treatment until symptoms emerge. This study analyzes the cost-effectiveness of
the pre-emptive therapy model in patient care dollars per quality-adjusted life years (QALY).
PATIENTS AND METHODS: Utilization and outcome data were compiled as a retrospective cohort study of 96
pediatric patients receiving HSCT at University of California Los Angeles Pediatric Hematology/Oncology
Department between the years 2006 and 2010. Two-decision tree models were constructed for each the pre-
emptive model and the deferred model wherein costs and probability assumptions were based on either previ-
ously published literature or calculated from this study cohort.
RESULTS: The pre-emptive model resulted in a five-year survival of 71%, during which time 4% of patients
were found to be EBV viremic, while 33% were found to be CMV viremic. The average actual cost of EBV/
CMV virology screening per patient in the cohort following the pre-emptive model was $9699 while the
expected cost following the deferred model was $19,284. This results in an incremental cost effectiveness ratio
illustrating pre-emptive model cost-savings of $2367/QALY.
CONCLUSION: These results support the financial viability and prudence of scheduled screening for subclin-
ical viremia for achieving optimal outcomes in a cost-effective manner in the pediatric HSCT population.HThe reality of opportunistic viral infections inimmunocompromised transplant populationshas been a point of robust research and dis-
cussion in recent years. In the hematopoietic stem cell
transplant (HSCT) patient population two com-
monly afﬂicting viruses are Epstein–Barr virus
(EBV) and cytomegalovirus (CMV), both of the gam-
ma herpesvirus family. These viruses are known to
establish latent infections in their host after an initial
acute disease and both are ubiquitous in both healthy
and ill populations with positive serologies in up to
90% and 81% of the adults for EBV and CMV
respectively.1,2 These viruses uncommonly result in
serious disease in the immunocompetent host, as spe-
ciﬁc clonally expanded antiviral CD8+ cytotoxic T-
lymphocytes control viral replication by targeting theematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.B-lymphocytes and monocytes that harbor the latent
viral particles and are thus adorned with viral nuclear
antigens.3 However, it is well documented that the
iatrogenic immunosuppression implicated in HSCT
gives rise to conditions amenable to viral reactivation
and replication, leading to a viremic state occasionally
followed by clinical disease.4–6 It is believed that this
is facilitated by the relative T-cell depletion in propor-
tion to latent-viral containing B-cells which is created
in vivo by way of antihuman thymocyte globulin
(ATG) administration or ex vivo by way of T-cell de-
pleted graft marrow, both common strategies to coun-
teract potential graft-vs-host disease.7,8
Speciﬁcally concerning CMV, multiple studies
that show the highest incidence of CMV viremia
(60–80%) and disease are in those patients who werecom 81
82
original research report PRE-EMPTIVE VIROLOGY SCREENING
CMV seronegative but received a graft from a CMV
seropositive donor (D+/R), with a median time to
seroconversion between the 2nd and 5th week after
transplant.9 CMV disease can manifest in a patient
in multiple ways: fever, pneumonitis, pancreatitis,
colitis, chorioretinitis, meningoencephalitis, marrow
suppression, or elevation in liver enzymes.9,10 On
the other hand, the most concerning disease impli-
cated in EBV reactivation is post-transplant lympho-
proliferative disorders (PTLD). PTLD is a
heterogeneous group of disorders which can include
benign polyclonal hyperplasia but most commonly
this PTLD takes the form of monomorphic Non-
Hodgkin’s Lymphoma, particularly diffuse large B-cell
type.11 Presentation might include fever or a sepsis
syndrome, but can quickly transform into a lym-
phoma presentation involving nearly any organ.
PTLD has a 1% incidence in bone marrow transplant
recipients in the ﬁrst 10 years post-transplant with
highest incidence one to ﬁve months after transplant
and the majority developing within the ﬁrst year.4
Pediatric patients are at particular risk of PTLD as
they are more likely to be seronegative at time of
transplant, and thus this incidence risk increases to
25% in pediatric patients receiving HLA-matched
unrelated donors or mismatched family members.12,13
Recent advances in polymerase chain reaction
(PCR) clinical laboratory assays have allowed for
detection, ampliﬁcation, and quantiﬁcation of viral
nucleic acids. This has allowed for routine monitoring
of HSCT patients for a viremia that might portend
the development of viral disease, thus allowing for
pre-emptive therapy which recent evidence has shown
to be more effective at prevention of morbidity and
mortality than a deferred therapy model in which
treatment is instigated by evidence of clinical disease.8
In conformance with these studies, clinicians in Uni-
versity of California Los Angeles (UCLA) Pediatric
Hematology/Oncology Department utilize routine
EBV and CMV PCR screening of their pediatric
HSCT population, initiating therapy upon evidence
of viremia. However, these viral assays and the resul-
tant treatments are not without signiﬁcant cost, both
in terms of healthcare dollars as well as therapy-re-
lated toxicity in a patient whose viremia might other-
wise resolve without treatment or clinical disease.
Accordingly, this study contains a cost-effectiveness
analysis to assess the efﬁcacy in terms of an incremen-
tal cost-effectiveness ratio (ICER) and quality-ad-
justed life years (QALYs) of pre-emptive viral
therapy requiring routine screening as utilized at
UCLA versus deferred viral assays and therapy.HematoMATERIALS AND METHODS
Study population
This is a retrospective cohort study assembling the
costs and outcomes of pediatric HSCT patients trans-
planted between 2006 and 2010 by the UCLA Pediat-
ric Hematology Oncology service. Institutional Review
Board approval was secured for outcome studies
involving this patient population. Of the 108 patients
transplanted during this time period, 12 were excluded
from the study due to insufﬁcient records accessible
during the period of UCLA’s transition to electronic
medical records in 2005. Thus, the study population
constituted 96 patients below the age of 21 at the time
of transplant who received their graft and subsequent
post-transplant care at UCLA’s Center for Health Sci-
ences or Ronald Reagan Hospital and associated out-
patient clinics. The patient characteristics and
indications for transplant are outlined in Table 1.
During their time as inpatients after transplant, pa-
tients undergo biweekly quantitative PCR assays for
CMV and EBV viral copy numbers. After discharge,
there are routine clinic visits once every two weeks
for the ﬁrst 100 days after transplant, then once a
month up until 1 year after transplant, then once every
three months until 5 years after transplant, followed
by once yearly thereafter. Patients continue receiving
EBV and CMV PCR evaluations at each clinic visit
until 1 year after transplant. In adhering to this rou-
tine of EBV and CMV quantitative screening and ini-
tiating therapeutic interventions for evidence of
viremia, clinicians at UCLA are implementing a pre-
emptive treatment algorithm and therefore their
PCR assay utilization patterns and associated costs
are a subject of analysis in this study.Assay utilization and cost
For the purpose of this study, each patient’s trans-
plant course was divided into three segments to cate-
gorize the timing of virology testing: pre-transplant
was the point of initial assessment until transplant;
peri-transplant was the period from the date of trans-
plant to 100 days after transplant; and post-transplant
was 100 days after transplant until January 2012
when this study was performed. The peri-transplant
period was bounded by 100 days after transplant as
this is the clinically signiﬁcant time frame after which
a patient’s immune system is most commonly fully
reconstituted.14 The replicative virology tests drawn
on our patient population were Quantitative CMV
PCR, Qualitative PCRs, CMV DNA Quantitation,
CMV Early-Antigen, Quantitative EBV PCR, andl Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
Table 2. Cost assumptions centers for medicare and medicaid services
(CMMS) reimbursement rates. $ USD (2010 US dollars).
CMMS reimbursement rates ($USD)
Virology quantitative PCR $60.67
Virology qualitative PCR $49.71
CMV IgG titers $20.39
CMV IgM $23.86
EBV EA IgG $18.53
EBV VCA antibody titers $27.69
EBV EBNA IgG $21.67
Table 1. Study population characteristics.
Characteristics:
Sample size 96
Avg age at HSCT 9y
Gender:
Male 62
Female 34
Ethnicity:
Caucasian 30
Hispanic 49
Asian 8
African-American 9
HSCT indication:
Acute Lymphoblastic Leukemia 26
Acute Myeloid Leukemia 20
Tumor 18
Lymphoma 8
Immunodeficiency 8
Chronic Myeloid Leukemia 5
Hemaglobinopathy 3
Other 8
Donor:
Matched Unrelated Donor 53
Self 24
Sibling 19
Graft Source:
Cord 42
Marrow 32
Peripheral 22
Outcomes:
CMV Viremia 32
EBV Viremia 4
CMV Disease 5
EBV Disease 0
PRE-EMPTIVE VIROLOGY SCREENING original research reportEBV DNA Quantitation. The serology tests of inter-
est were CMV IgG, CMV IgM, EBV Early-Antigen
IgG, EBV VCA IgG, EBV VCA IgA, EBV VCA
IgM, and EBV EBNA IgG.
Assay cost data was based on Center for Medicare
and Medicaid Services reimbursements to UCLAHematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.Hospital Systems as publicly available and conﬁrmed
by representatives from our central clinical labora-
tory.15 All prices are expressed in 2010 USD
(Table 2).
Cost-efﬁciency analysis
A decision tree model was created comparing the po-
tential outcome space of hypothetical patients under-
going transplant following one of two algorithms: pre-
emptive virology therapy vs. deferred virology therapy
(Figure 2). Given that UCLA’s Pediatric Hematol-
ogy/Oncology department has utilized routine screen-
ing and pre-emptive therapy for many years, their
historical cost and utilization data was incorporated
to represent the pre-emptive model while the deferred
model was an extrapolation from existing cost data
but under different utilization assumptions. For the
pre-transplant period, screening costs in the deferred
model were assumed to match those in the UCLA
pre-emptive experience, as serologic workup would
likewise be required. In addition, screening costs were
built into the deferred model during patient disease
states, capturing the resultant increased surveillance.
The increase in surveillance assumptions were derived
from the assay utilization patterns observed in our
study, and outlined in the Results section to follow.
In both models, all utility assumptions of various dis-
ease states and the probability of a given disease state
were derived from previously published literature or
data presented in this study.5,16–20 The utility of
states in which the child is asymptomatic and can
be discharged home on oral medications (as with
asymptomatic CMV viremia requiring oral valganci-
clovir) was assumed to be 1, except in states of toxic-
ity. In the absence of toxicity or recurrent disease, life
expectancy was assumed to be 78.5 years.21 Screening
costs were forecast given an assumed age of transplantcom 83
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of 9 years old as this was the average age in our sample
at transplant. Cost assumptions for anti-viral therapy
were incorporated in both models given that probabil-
ity differences of required treatments would impact
overall cost of the paradigm. Extracted from existing
literature, costs were incorporated for treating CMV
disease in event of patient recovery or death, for treat-
ing false positive elevations in CMV viral copy num-
bers, and for treating the potential non-Hodgkin’s
lymphoma arising from PTLD.16,20 These cost
assumptions are outlined in Figure 2.
The primary output of interest in this cost-efﬁ-
ciency analysis was the $USD per QALY difference
between the pre-emptive model and the deferred
model: the incremental cost-effectiveness ratio
(ICER).
ICER ¼ CostPre-emptive  CostDeferred
QALYPre-emptive QALYDeferred
The analytic horizon of this analysis extended to
outcomes attributable to the progression of EBV/
CMV viremia or disease only. Given that this analysis
focuses solely on the incremental cost-effectiveness ra-
tio of routine virology screening vs. deferred therapy,
all cost and utility components shared between the
two protocols were not modeled. For example, no at-
tempt was made to incorporate QALY implications of
non-engraftment or primary disease progression, as
the risk of these costs do not differ markedly between
the two models and thus would not have an impact on
the difference between the two models: the ICER.
A sensitivity analysis was performed by varying
utility and probability assumptions across the range
of values supported by published literature: the rate
of PTLD in the deferred group varied between 1%
and 17%, the rate of EBV viremia seen varied between
1% and 48%, the CMV progressing to death varied up
to 40%, and cost of virology assays increased by
50%.4,22
Outcomes
CMV viremia was deﬁned as a CMV Qualitative/
Quantitative/Quantitation PCR being elevated above
zero in two consecutive assays in the peri-transplant
or post-transplant period. CMV disease was deﬁned
as evidence of CMV viremia in conjunction with evi-
dence of an organ speciﬁc infection without another
source (pneumonitis, pancreatitis, colitis, chorioretini-
tis, meningoencephalitis, marrow suppression, or ele-
vation in liver enzymes). In adherence with the pre-
emptive therapy protocol, in all patients in our sam-
ple, evidence of asymptomatic CMV viremia was trea-
ted with three months of oral valganciclovir. The costHematoassumptions for three months of valganciclovir in
2010 USD was $9,277.16 Evidence of CMV disease
was treated with roughly one month of intravenous
ganciclovir followed by several months of oral val-
ganciclovir. This cost was estimated to be $30,519.16
EBV Quantitative PCR threshold for considering
a positive test was 1000 copies/uL. When there was
evidence of EBV viremia, the treatment team re-
sponded by lowering immunosuppression – most
commonly a reduction in prednisone or cyclosporine
– and increasing viremia surveillance. In all cases, this
led to full resolution of viremia without development
of EBV-related disease.RESULTS
Assay utilization
An average of 28 virology assays were performed per
patient at UCLA as a part of their pre-transplant eval-
uation and peri-transplant workup for the ﬁrst
100 days (Table 3). The majority was serologic stud-
ies in the pre-transplant period (ﬁve per patient) and
viral replicative assays in the peri-transplant period
(20 per patient). In terms of assay cost per patient,
this equates to an average of $1,501 per patient
through the ﬁrst 100 days after transplant. After this,
in the post-transplant period, there were on average
three virology tests performed on these patients every
month, the majority of these being virus replication
assays. This came to an average cost of $176 per pa-
tient per month in the post-transplant period (Ta-
ble 3). For patients who were CMV PCR(), 27
CMV PCR assays were performed per patient, while
32 patients who were CMV PCR(+) (27 of whom
never developed clinical disease) 41 CMV PCR assays
per patient were performed, an increase of 50%. Sim-
ilarly, the presence of EBV viremia increased the EBV
PCRs performed on a patient three-fold, from 17 for
EBV PCR() patients, to 55 for those who at one
time were documented as viremic.
Patient outcomes
The average length of patient clinical following in this
study was 24 months (Figure 1). The ﬁve-year overall
survival in the study population was 71%. Of the 96
patients in this study, four (4.2%) were found on
EBV PCR to have EBV viremia on >1000 copies/
uL. However, no patients in our study went on to de-
velop PTLD during this study period. Additionally,
32 patients (33%) were found to have CMV viremia,
while ﬁve went on to have symptomatic CMV disease
subsequent to transplant (Table 1). This incidence
matches published data in adult HSCT patients.5l Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
Table 3. Study population assay utilization and cost results per patient
$ USD (2010 US dollars).
# Of
assays
Avg assays
per Pt
$ USD Avg $USD
per Pt
Pre-transplant
Serologies
CMV 304 3.2 $6,507.39 $67.79
EBV 156 1.6 $3,888.04 $40.50
Viral replication
CMV 182 1.9 $11,063.08 $115.24
EBV 86 0.9 $5,217.62 $54.35
Peri-transplant
Serologies
CMV 11 0 $241.64 $2.52
EBV 17 0 $388.55 $4.05
Viral replication
CMV 1981 13 $75,126.98 $782.57
EBV 687 7 $41,680.29 $434.17
Post-transplant
Serologies (per month)
CMV 46 0 $68.11 $0.71
EBV 2 0 $55.32 $0.58
Viral replication
CMV 164 2 $9,958.60 $103.74
EBV 112 1 $6,810.64 $70.94
PRE-EMPTIVE VIROLOGY SCREENING original research reportTwo of the patients in the study were diagnosed with
CMV colitis; two were diagnosed with hemorrhagic
cystitis; and one was diagnosed with CMV
pneumonia.
Cost-effectiveness analysis
Our analysis indicates that pre-emptive screening and
therapy will result – as illustrated by the UCLA expe-
rience – in an average of 28 serologic and PCR assays
through the peri-transplant period. This will be fol-
lowed by an average of three assays per month in
the immediate post-transplant period, at a cost of
$176 per month which tapers off as the post-trans-
plant period lengthens. When assuming an age atHematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.transplant of nine (the average age in our sample)
and the pre-emptive model probabilities and un-
weighted cost assumptions outlined in Figure 2, the
pre-emptive therapy model sums to an average prob-
ability-weighted cost per patient of $9,699 until the
patient turns 21 years old. Alternatively, the deferred
therapy model achieves a lower cost through the pre-
transplant period of $278 per patient; however, the
cost of this model subsequently rises when adhering
to the probabilities of high-cost disease states outlined
in Figure 2: the projected total cost per patient of the
deferred model is $19,284. Using the aforementioned
utility and probability assumption, the pre-emptive
model illustrated probability-weighted utility beneﬁt
of 0.958 versus 0.927 of the deferred model. Putting
this data together, our cost-efﬁciency analysis of the
pre-emptive model as experienced at UCLA and rep-
resented in Figure 2 revealed a QALY of 63.8 years
while the deferred model illustrated a QALY of
59.7 years after transplant. Incorporating the actual
costs of UCLA’s pre-emptive model and the forecast
costs of the deferred model with these QALY values,
the ICER of the pre-emptive model over the deferred
model calculated yielded ($2,367)/QALY. Perform-
ing a sensitivity analysis by varying the probabilities
according to ranges outlined in the preceding Meth-
ods section, it was illustrated that in all conditions
the ICER remained <$50,000/QALY, indicating
pre-emptive therapy cost-effectiveness across the out-
come space. The maximum recorded ICER was
$5740/QALY.DISCUSSION
In this study, we outline a cost-efﬁciency analysis in
which scheduled screening for CMV/EBV followed
by treatment of asymptomatic viremic pediatric
HSCT patients is compared to a deferred treatment
model in which patients are not subject to routine vir-
al PCR assays but are treated when CMV/EBV dis-
ease clinically manifests. As illustrated by an
incremental cost-effectiveness ratio of ($2,367)/
QALY, the pre-emptive therapy model currently in
use at UCLA is cost effective, as deﬁned by the stan-
dard: ICER < $50,000/QALY.24 Not only is it cost
effective, the negative number indicates that the pre-
emptive therapy paradigm saves dollars per patient
due to lowering the likelihoods of high-cost disease
states. Furthermore, sensitivity analyses in which
probability and utility assumptions were varied across
the spectrum of available data illustrated that this cost
effectiveness was maintained regardless of reasonablecom 85
Figure 1. Study population overall survival.
Figure 2. Decision tree models outlining the potential treatment courses for hypothetical individuals subject either the Pre-emptive and Deferred Treatment paradigms.
Probability of occurrence, patient utility and cost of that outcome space, along with assumption citations have been listed. All nodes reflect introduction of chance. *
indicates data presented in this study.
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authors’ works which show efﬁcacy in prevention of
morbidity/mortality with the pre-emptive model,Hematothese results indicate that this paradigm achieves the
same results in an inexpensive, cost-effective, and
cost-saving manner.l Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
PRE-EMPTIVE VIROLOGY SCREENING original research report
As is often the case in cost-effectiveness analyses, the
older a patient is at the moment of intervention, the
fewer quality-adjusted life years intervention begets.
However, sensitivity analysis within this model illus-
trates that as the age of the patient at transplant
increases, the smaller the QALY difference becomes
between the two screening paradigms; thereby render-
ing the lower cost pre-emptive screening paradigm
more cost-effective. Put another way, the older a
patient is at transplant the more similar their QALY
outlook becomes regardless of screening cadence, thus
making pre-emptive screening the more cost-effective
approach as it is the fundamentally less costly approach.
Assay utilization patterns
An inherent risk in a practice of surveillance assays
with no clinical instigator is the potential for assay
overutilization. For example, as clinicians are accli-
mated to routine ordering of EBV and CMV assays
on HSCT transplant patients, habitual diagnostic
orderings might occur at inappropriate times and in
unsuitable quantities. This is reﬂected in the data ac-
quired from UCLA’s assay utilization. For example, in
several instances serologies were ordered in the peri-
transplant and post-transplant periods in our patient
sample in patients in whom seroconversion had been
well-documented previously in their hospital course,
or who had recently received IVIG. Furthermore, in
our study population, patients who were D/R,
had CMV PCRs ordered in the peri-transplant and
post-transplant period at the same rate as the D+/
R and D+/R+ cohorts. Given that the EBPG Ex-
pert Group on Renal Transplant suggest D+/R
pts are the highest risk, perhaps the future adoption
of these screening guidelines can aid in future cost
containment.
Therapy utilization patterns
In addition, the pre-emptive model creates great cost
not simply from increased assay utilization, but also
from increased therapy in patients who would other-
wise self-resolve their viremic state. As previously dis-
cussed, there was a 50% increase in CMV PCR
testing in those patients who at one point were
CMV PCR(+). As a result, testing CMV PCR(+)
led to an average increased screening cost of $4,176
per CMV PCR(+) patient. Utilizing previously pub-
lished rates of CMV disease without treatment, 10 of
32 viremic patients may not have developed clinical
disease and were thereby treated unnecessarily for a
viremia that would resolve without therapy.16,23
Therefore, a patient who is CMV PCR(+) and who
is resultantly screened more frequently and treatedHematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.constitutes a false-positive inherent in the pre-emptive
screening paradigm. Combining the costs of increased
screening and the therapy cost assumptions above,
these false-positives result in $34,694 increase in
non-weighted cost per CMV PCR(+) patient.
Weighting this cost of a false-positive by the probabil-
ity a false-positive will occur reveals that $3,425 of the
$9,699 pre-emptive therapy weighted-cost (35%)
comes from the existence of false-positives: treating
and screening patients who are CMV(+) who would
likely not have developed clinical CMV disease
regardless of therapy.
Study limitations
This study makes use of Medicare reimbursements as
a proxy for cost of a given assay. While this is a com-
mon approach for calculating the cost of care provi-
sion, this should more appropriately be recognized
as the cost to the government of care provision,
whereas cost to the hospital would be better ac-
counted for by factoring in cost-to-charge ratios for
University of California. But access to this data is lim-
ited. Furthermore, in addition to the direct cost of the
assay that should be accounted for in calculating the
costs associated with the current surveillance practice
is the laboratory technician’s opportunity costs for
running each assay. However, given the negligible
incremental time required in performance of the lab-
oratory assays of scale, this was deemed to be an insig-
niﬁcant additional cost that would not alter the
conclusions of this study. All told, the costs discussed
in this publication are likely to be an underestimation
of true costs to the hospital providing care.
Future directions
This study compares two paradigms for viremia
screening in the HSCT population but with the same
resultant treatment between both arms: a reliance on
anti-virals in the case of CMV and a reduction in
immunosuppression in the case of EBV. Concomitant
to this study, efforts are underway to explore the med-
ical and cost of novel therapies for CMV-related dis-
eases and PTLD in the HSCT pediatric population.
For example, EBV-speciﬁc cytotoxic T Lymphocytes
for the prevention or treatment of PTLD has recently
been shown to be medically efﬁcacious, low cost, and
safe. While the $6,095 upfront cost of EBV-speciﬁc T
cells quoted in the cited study and the natural low-
incidence of PLTD are concerning for a cost-ineffec-
tive intervention as compared to conventional pre-
emptive screening and resultant anti-viral therapy, fu-
ture studies may evaluate this as-of-yet unexplored
cost-effectiveness comparison.com 87
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Previously, researchers have shown the reduction in
morbidity/mortality associated with pre-emptive ther-
apy – routine viral screening with antiviral therapy
initiated at the documentation of viremia before clin-
ical disease is illustrated – over a deferred treatment
paradigm whereupon antiviral therapy is initiated
with the onset of clinical disease. This study builds
upon existing evidence in support of pre-emptive ther-
apy in illustrating that routine EBV and CMV
screening and pre-emptive therapy increases patientHematoutility, quality-adjusted life years, is cost-effective
and furthermore is cost-saving when compared to a
deferred therapy model.FUNDING SOURCES
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